Silence Therapeutics plc, a leading biotechnology company specializing in precision-engineered medicines for treating diseases, has announced a significant milestone in its partnership with Hansoh Pharmaceutical Group Company Limited

4D Molecular Therapeutics has obtained FDA clearance for its Investigational New Drug Application for 4D-175, an intravitreal genetic medicine utilizing the R100 vector, intended for treating geographic atrophy

Bristol Myers Squibb announced today that the U.S. Food and Drug Administration has granted accelerated approval for KRAZATI® in combination with cetuximab as a targeted treatment for adult patients

Takeda announced today that the European Commission has approved FRUZAQLA as a monotherapy for the treatment of adults with metastatic colorectal cancer (mCRC) who have previously undergone standard therapies

Sanofi and Biovac, a South African biopharmaceutical company based in Cape Town, have announced a partnership to manufacture inactivated polio vaccines (IPV) locally in Africa. This collaboration

Kyverna Therapeutics, Inc. has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application concerning KYV-101, an autologous, fully human anti-CD19 chimeric antigen receptor

Sobi® has received approval from the European Commission for ALTUVOCT™, a replacement therapy designed for treating and preventing bleeds, as well as for perioperative prophylaxis in individuals with hemophilia

The CMT Research Foundation, committed to finding treatments for Charcot-Marie-Tooth disease (CMT), has teamed up with ReviR Therapeutics. Their collaboration aims to develop small molecule therapies

AbbVie has announced that the U.S. Food and Drug Administration has approved SKYRIZI® for adults suffering from moderately to severely active ulcerative colitis. This marks the first approval

Assembly Biosciences, Inc., a biotechnology company specializing in novel therapies for serious viral diseases, has announced the commencement of dosing for the Phase 1b trial of ABI-4334